Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: Advantages and disadvantages

References

• Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: Results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol 2005; 141(1)1–9
   PubMed Web of Science ®Google Scholar
• Burt RK, Marmont A, Oyama Y, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: The evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006; 54(12)3750–3760
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Petri M, Smith BD, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998; 129(12)1031–1035
   PubMed Web of Science ®Google Scholar
• Abbott JD, Huang Y, Liu D, et al. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004; 110(21)3300–3305
   PubMed Web of Science ®Google Scholar
• Duester G. Genetic dissection of retinoid dehydrogenases. Chem Biol Interact 2001; 130–132(1–3)469–480
   PubMedGoogle Scholar
• Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984; 44(11)5156–5160
   PubMed Web of Science ®Google Scholar
• Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990; 75(10)1947–1950
   PubMed Web of Science ®Google Scholar
• Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995; 85(10)2742–2746
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005; 35(9)869–879
   PubMed Web of Science ®Google Scholar
• Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295(5)527–535
   PubMed Web of Science ®Google Scholar
• Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003; 48(1)166–173
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005; 365(9471)1647–1656
   PubMed Web of Science ®Google Scholar
• Thomas ED, Storb R, Fefer A, et al. Aplastic anaemia treated by marrow transplantation. Lancet 1972; 1(7745)284–289
   PubMed Web of Science ®Google Scholar
• Thomas ED, Storb R, Giblett ER, et al. Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol 1976; 4(2)97–102
   PubMedGoogle Scholar
• Sensenbrenner LL, Steele AA, Santos GW. Recovery of hematologic competence without engraftment following attempted bone marrow transplantation for aplastic anemia: Report of a case with diffusion chamber studies. Exp Hematol 1977; 5(1)51–58
   PubMedGoogle Scholar
• Gmur J, Vonfelten A, Rhyner K, et al. Autologous hematologic recovery from aplastic anemia following high dose cyclophosphamide and HLA-matched allogeneic bone marrow transplantation. Acta Haematol 1979; 62: 20–24
   Google Scholar
• Speck B, Cornu P, Jeannet M, et al. Autologous marrow recovery following allogeneic marrow transplantation in a patient with severe aplastic anemia. Exp Hematol 1976; 4(3)131–137
   PubMedGoogle Scholar
• Baran DT, Griner PF, Klemperer MR. Recovery from aplastic anemia after treatment with cyclophosphamide. N Engl J Med 1976; 295(27)1522–1523
   PubMedGoogle Scholar
• Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood 1996; 87(2)491–494
   PubMedGoogle Scholar
• Brodsky RA, Sensenbrenner LL, Smith BD, et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001; 135(7)477–483
   PubMedGoogle Scholar
• Jaime-Perez JC, Gonzalez-Llano O, Gomez-Almaguer D. High-dose cyclophosphamide in the treatment of severe aplastic anemia in children. Am J Hematol 2001; 66(1)71
   PubMedGoogle Scholar
• Li Z, Yin S, Xie S, et al. Treatment of severe aplastic anemia using high-dose cyclophosphamide alone in China. Haematologica 2000; 85: E06
   Google Scholar
• Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in severe aplastic anaemia: A randomised trial. Lancet 2000; 356(9241)1554–1559
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Chen AR, Brodsky I, Jones RJ. High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Exp Hematol 2004; 32(5)435–440
   PubMedGoogle Scholar
• Savage WJ, DeRusso PA, Resar LM, et al. Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide. Pediatr Blood Cancer 2007; 49(7)947–951
   PubMedGoogle Scholar
• Brodsky R, Chen A, Dorr D. High dose cyclophosphamide for severe aplastic anemia: Safety and long term follow-up [abstract]. Blood 2005; 106: 41a–42a
   Google Scholar
• Gladstone DE, Prestrud AA, Pradhan A, et al. High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus 2002; 11(7)405–410
   PubMedGoogle Scholar
• Moyo VM, Smith D, Brodsky I, et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002; 100(2)704–706
   PubMed Web of Science ®Google Scholar
• Nousari HC, Brodsky RA, Jones RJ, et al. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol 1999; 40(5 Pt 1)750–754
   PubMedGoogle Scholar
• Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 2000; 43(6)1065–1069
   PubMedGoogle Scholar
• Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: “Rebooting” with high-dose cyclophosphamide. Ann Neurol 2003; 53(1)29–34
   PubMed Web of Science ®Google Scholar
• Gladstone DE, Brannagan TH, 3rd, Schwartzman RJ, et al. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry 2004; 75(5)789–791
   PubMed Web of Science ®Google Scholar
• Brannagan TH, 3rd, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002; 58(12)1856–1858
   PubMed Web of Science ®Google Scholar
• Gladstone DE, Zamkoff KW, Krupp L, et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 2006; 63(10)1388–1393
   PubMedGoogle Scholar
• Oliva-Hemker MM, Loeb DM, Abraham SC, Lederman HM. Remission of severe autoimmune enteropathy after treatment with high-dose cyclophosphamide. J Pediatr Gastroenterol Nutr 2003; 36(5)639–643
   PubMedGoogle Scholar
• Brodsky RA, Fuller AK, Ratner LE, et al. Elimination of alloantibodies by immunoablative high-dose cyclophosphamide. Transplantation 2001; 71(3)482–484
   PubMedGoogle Scholar